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Introduction
The clinical benefit of anticoagulant treatment for 
various indications is offset by the risk of bleeding. 
The impact of bleeding related to vitamin K antagonist 
(VKA) use, in terms of patients' discomfort or 
temporary disability and in terms of both medical 
and socio-economic resources is not negligible1-4. 
However, the majority of studies have focused on 
major bleeding, used obsolete definitions of bleeding 
and have not distinguished between clinically relevant 
non-major bleeding (CRNMB) and minor events2,3. The 
International Society on Thrombosis and Haemostasis 
provided a standard definition of CRNMB in 2015 as 
those events that are not major but require any kind of 
medical intervention5.
Over the last decade, many randomised phase III 
studies on direct oral anticoagulants (DOAC) have 
reported incidences of CRNMB in patients treated for 
atrial fibrillation or venous thromboembolism6-14. The 
rates of CRNMB in these studies have varied between 
4 and 12%15-17. In the observational studies, the rates of 
major bleeding were about 5% and those of CRNMB 
varied between 10 and 20%18-20. Overall, compared with 
major bleeds, CRNMB tend to occur more frequently 
and are associated with a lower mortality6-14,19. However, 
the burden of care arising from CRNMB, for both the 
patient and the health system, is difficult to estimate in 
clinical practice.
We carried out a prospective, observational, 
multicentre, cohort study to assess the clinical 
characteristics, management and outcomes of CRNMB 
occurring in patients while on oral anticoagulants.
Materials and methods
Consecutive patients hospitalised for CRNMB 
occurring during treatment with either a DOAC or 
VKA were included in this study. CRNMB was defined 
according to the criteria set out by the International 
Society on Thrombosis and Haemostasis5. 
The following data were collected: each patient's 
features and comorbidities, indication for anticoagulant 
therapy, site of bleeding, symptoms on admission, 
haemodynamic parameters, relevant laboratory results 
(International Normalised Ratio [INR], haemoglobin 
count, renal function, etc.), medical treatment (red 
blood cells, plasma, haemostatic agents), interventions 
(surgery, endoscopy, endovascular treatment), duration 
of hospital stay and clinical status at discharge. The 
management of DOAC- and VKA-related CRNMB was 
at the discretion of the attending physicians.
The study protocol was approved by local Ethical 
Committees. 
Frequency data are presented as proportions with 
95% confidence intervals (95% CI). Continuous data are 
shown as means ± standard deviations (SD). Student`s 
t-test test and the χ2 test were used for comparisons 
of continuous and categorical variables, respectively. 
Statistical analyses were performed using SPSS 21.0 
(IBM Corporation, Armonk, NY, USA).
Results 
Between September 2013 and August 2016, 205 
patients were included in the study (50 taking a 
DOAC and 155 taking a VKA). The main indication 
for anticoagulant treatment was atrial fibrillation 
(81% of all patients) and the mean age of the patients 
was 78±11 years. The most prevalent comorbidities 
were hypertension, vascular disease, a history of 
bleeding, renal failure and heart failure. DOAC and 
VKA patients differed only by their prevalences of 
renal failure (12% vs 32%, respectively; p=0.006) 
(Table I). 
The most commonly reported types of bleeding 
were macroscopic haematuria, skin or subcutaneous 
haematomas, epistaxis, rectal blood loss and muscle 
haematomas (Table II). The majority of bleeds occurred 
spontaneously, while 24% occurred after trauma or 
invasive medical procedures (Table I).
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Table I - Patients' features and bleeding sites.
Overall
N=205, n (%)
DOAC
N=50, n (%)
VKA
N=155, n (%)
Age, mean±SD
range
78±11
29-96
78±10
40-96
78±11
29-93
Male gender 112 (55) 33 (66) 79 (51)
Indication for anticoagulation
   Atrial fibrillation
   Venous thromboembolism
166 (81)
11 (6)
47 (94)
3 (6)
119 (77)
10 (6)
Hypertension 144 (70) 32 (64) 112 (72)
Renal failure 55 (27) 6 (12) 49 (32)
Diabetes 40 (19) 11 (22) 29 (19)
Previous bleeding 62 (30) 15 (30) 47 (30)
Previous stroke 33 (16) 10 (20) 23 (15)
Heart failure 48 (23) 15 (30) 33 (21)
Vascular disease 69 (34) 13 (26) 56 (36)
Malignancy 32 (16) 9 (18) 23 (15)
NSAID/antiplatelet use 17 (9) 6 (12) 13 (8)
Site
   Gastrointestinal 
   Genitourinary
   Respiratory tract
   Intramuscular
   Skin/subcutaneous
   Other
49 (24)
38 (18)
50 (24)
23 (11)
36 (18)
9 (4)
20 (40)
17 (34)
6 (12)
1 (2)
5 (10)
1 (2)
29 (19)
21 (13)
44 (28)
22 (14)
31 (20)
8 (5)
Trauma 50 (24) 10 (20) 40 (26)
DOAC: direct oral anticoagulants; VKA: vitamin K antagonists; SD: standard deviation; NSAID: 
non-steroidal anti inflammatory drugs.
Table II - Management strategies and outcomes according to bleeding site.
Bleeding site N Type of bleeding N Clinical managment Death
N (%)Interruption 
of the drug
N (%)
Endoscopy
N (%)
Procedures 
or surgery*
N (%)
RBC
N (%)
FFP/PCC
Gastrointestinal 49 Haematemesis 6 40 (82) 29 (59) 3 (6) 4 (8) 0/2 4 (8)
Melaena 8
Rectal 29
Anaemia 6
Respiratory tract 50 Haemoptysis 10 21 (42) 6 (12) 33 (66) 1 (2) 1/3 2 (4)
Epistaxis 32
Gingival 2
Pleural 6
Genitourinary 38 Macroscopic haematuria 36 32 (84) 10 (26) 5 (13) 1 (3) 1/1 1 (3)
Genital 2
Skin/subcutaneous 36 36 27 (75) - 3 (8) - 1/3 3 (8)
Intramuscular 23 23 19 (83) - 11 (48) - 0/3 -
Peritoneal/pelvic 8 8 8 1 3 - 0/4
Parotid gland 1 1 1 - - - -
RBC: red blood cells; FFP: fresh-frozen plasma; PCC: prothrombin complex concentrates; *minor surgery or surgery for cancer.
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Table III - Major cardiovascular events during hospitalisation after anticoagulant-associated clinically relevant, non-major 
bleeding.
Type of CV 
event
Gender/
age (years)
Indication 
for 
anticoagulants
Type 
of drug
Site of bleeding Procoagulants/
transfusions
Interruption 
of the drug
Time from 
bleeding 
(days)
Death
Acute coronary 
syndrome
M 
70 
Non-valvular 
AF
VKA Lower gastrointestinal 
(rectal)
None/none Yes 1 No
F 
87 
Non-valvular 
AF
VKA Upper gastrointestinal 
(haematemesis)
None/none Yes 1 No
F 
90
Non-valvular 
AF
DOAC Lower gastrointestinal 
(rectal)
None/none Yes 1 Yes
F
83
VTE VKA Muscle haematoma Vit K/none Yes 2 No
M 
77
Non-valvular 
AF
VKA Haemoptysis Vit K/none Yes 1 Yes
Ischaemic stroke M 
82
Other VKA Epistaxis None/none Yes NA No
Systemic 
embolism
M 
82
Non-valvular 
AF
VKA Upper gastrointestinal 
(haematemesis)
Vit K/none Yes 2 No
CV: cardiovascular; AF: atrial fibrillation; VTE: venous thromboembolism; VKA: vitamin K antagonist; DOAC: direct oral anticoagulant; Vit K: vitamin 
K; NA: not available.
On admission, anticoagulant therapy was interrupted 
in 148 patients (72% of all patients; 76 and 71% of 
DOAC and VKA patients, respectively). About 3% 
of patients were given one unit of red blood cells. 
Overall 19 patients, all taking VKA, received fresh-
frozen plasma (3 patients) or prothrombin complex 
concentrates. Tranexamic acid was administered to five 
patients (3 DOAC patients). 
Bleeding required minor surgery or interventional 
procedures in 92 cases (45%; 46 and 44% of DOAC 
and VKA patients, respectively): cauterisation or 
packing for nasal bleeding in 28 patients and endoscopy 
for gastrointestinal or genitourinary bleeding in 39 
patients. The management and outcome of bleeding 
events are reported in Table II, divided according to site 
of bleeding. DOAC patients more frequently required 
endoscopy for the management of CRNMB, while VKA 
patients more frequently required angiography or other 
procedures (pleural drainage, nasal packing, and other).
Seven patients (4%) experienced a major 
cardiovascular event during their stay in hospital, 
most after gastrointestinal bleeding (Table III). These 
events were acute coronary syndrome (n=5), systemic 
embolism (n=1) and ischaemic stroke (n=1). None of 
these seven patients had been treated with prothrombin 
complex concentrates to manage their acute bleeding. 
Ten patients died in hospital (5%; 6% of DOAC patients 
and 4% of VKA patients). The mean time to death was 7 
days. Two patients died of heart failure (1 DOAC patient), 
two of acute coronary syndrome (1 DOAC patient), three 
of infections, two of respiratory failure and one of cancer. 
The mean time spent in hospital was 8 days and 
was similar in DOAC and VKA patients (9 and 7 days, 
respectively). 
Discussion
Our study results indicated that CRNMB occurring 
while on oral anticoagulant therapy and requiring 
hospitalisation are not trivial for either patients 
or health care systems. Specifically, these events 
frequently require interventions or pharmacological 
management, may necessitate blood transfusions 
and, most importantly, are associated with a far from 
negligible risk of death and/or major cardiovascular 
complications. In fact, in our study, 45% of patients 
with CRNMB required minor surgery or interventional 
procedures (46% of DOAC patients) and 4% of patients 
had a major cardiovascular complication (1 DOAC 
patient) during their stay in hospital. Data from the 
Dresden NOAC registry pertaining to 379 CRNMB 
showed that the majority of the bleeds could be managed 
conservatively and surgical or interventional treatment 
was required in only 51 cases (13.5%). Procedures in 
that study mainly consisted of sutures after traumatic 
skin lesions, cauterisation of mucosal bleeding, and 
endoscopic treatment of gastrointestinal bleeding5. Only 
one patient experienced a major cardiovascular event5. 
The differences between our results and those from the 
Dresden NOAC registry may be partially accounted for 
by the different designs of the two studies: our study was 
based on patients with CRNMB admitted to hospital 
while the Dresden registry also included outpatients. 
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However, CRNMB not requiring surgery or 
interventional procedures can be considered clinically 
relevant because it causes distress to the patient and 
can lead to temporary interruption of anticoagulant 
therapy; such an interruption can contribute to the 
risk of arterial or venous embolic complications, as 
observed in our study.
Our study results support previous findings on 
differences between DOAC and VKA in terms of organ-
specific bleeding patterns. In fact, gastrointestinal and 
genitourinary CRNMB were more common among 
patients taking DOAC than among those taking VKA, 
whereas upper airway bleeding and intramuscular 
haematomas were more common in VKA patients than 
in DOAC patients. As a consequence, strategies for 
management of bleeding events differed between DOAC 
and VKA patients.
This study had some limitations. First of all, 
only patients hospitalised for CRNMB were studied. 
This selection of events with a more severe clinical 
presentation and course, and probably greater utilisation 
of healthcare resources, may have led to a bias. A 
significant proportion of patients experiencing CRNMB 
are managed as outpatients in real-life19. Moreover, this 
was an observational study and results from comparisons 
between DOAC and VKA patients should be interpreted 
with caution, as the number of DOAC-related events 
was limited and all therapeutic decisions were left to 
the discretion of the attending physicians. 
Conclusions 
In terms of management, duration of hospitalisation 
and in-hospital mortality, the burden arising from 
CRNMB occurring in clinical practice in patients taking 
DOAC or VKA was not trivial. Our study confirms 
the value of the recent definition of CRNMB by the 
International Society on Thrombosis and Haemostasis. 
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